Drug toxicity often goes undetected until clinical trials, the most costly and dangerous phase of drug development. Both the cultures of human cells and animal studies have limitations that cannot be overcome by incremental improvements in the drug testing protocols. A new generation of preclinical models - in form of integrated human tissue platforms, would be transformative to drug screening and predictive modeling of disease. This multiphase (UH2/UH3) proposal integrates in a novel and synergistic way some recent breakthroughs from four leading laboratories, towards developing a vascular/liver/cardiac microtissue system predictive of integrated human physiology. In the UH2 phase, we aim to establish iPS-based vascular, liver and cardiac microtissues providing (i) hierarchical tissue-specific architectures, (ii) functional representation of human biology of health, injury and disease, (iii) real-time biological readouts, and (iv) compatibility with high-throughput/high-content multi-tissue platforms for studies of drug toxicity and over long periods of time (e4 weeks). The work will be done using iPS-derived cells (to provide a large diversity of normal and disease genotypes) and using nondestructive monitoring of the tissue architecture and function (to provide real-time insights into the progression of cell and tissue responses). Our overall hypothesis is that tissue specific structure-function relationship can be achieved through control and biomimetic application of microenvironemental cues in vitro. Such microtissues will then be high-fidelity models for drug testing and toxicology. In the UH3 phase we aim to deploy an integrated cardiac/hepatic/vascular platform and demonstrate its utility for a broad range of genotypes and drugs. Towards these goals, we will pursue a set of coordinated aims with constant feedback, evaluation, and monitoring of the milestones.
Aim 1 is to develop cell-type specific labeling and sensing systems for on-line assessment of tissue architecture and cell function.
Aim 2 is to develop a perfusable branching vascular network serving as a model of the vascular bed and for assembling vascularized liver and cardiac tissues.
Aim 3 is to develop a liver module by assembling hepatic microtissues in hydrogel around the vascular tree.
Aim 4 is to develop a cardiac module by assembling matured cardiac microtissues in hydrogel around the vascular tree.
Aim 5 is to conduct studies of disease susceptibility, for the individual tissue modules and in the multi-tissue platform.
Aim 6 is to investigate human physiology and disease in multi-tissue platforms. This way, we aim to develop a radically new technology for studies of drugs in human tissue models. If successful, the proposed approach would radically enhance the translation of drug discovery into human applications, by enabling accurate preclinical data for better, faster and cheaper clinical trials.

Public Health Relevance

Broader Impact We propose to engineer three different microtissues highly resembling the structure and normal function of human capillary network, liver lobule and heart muscle, and to use these microtissues for screening of drugs and study of disease under conditions representative of whole bodyphysiology. To enable personalized approach to evaluation of drug regimens and study of disease, we will use adult stem cells derived from small samples of the patient's skin. This technology could greatly accelerate translation of discovery into new therapeutic modalities for the patients in need.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Exploratory/Developmental Cooperative Agreement Phase I (UH2)
Project #
3UH2EB017103-02S1
Application #
8729744
Study Section
Special Emphasis Panel (ZRG1-BST-N (50))
Program Officer
Hunziker, Rosemarie
Project Start
2012-09-30
Project End
2014-06-30
Budget Start
2013-09-15
Budget End
2014-06-30
Support Year
2
Fiscal Year
2013
Total Cost
$160,500
Indirect Cost
$15,000
Name
Columbia University (N.Y.)
Department
Biomedical Engineering
Type
Schools of Engineering
DUNS #
049179401
City
New York
State
NY
Country
United States
Zip Code
10027
Ma, Stephen P; Vunjak-Novakovic, Gordana (2016) Tissue-Engineering for the Study of Cardiac Biomechanics. J Biomech Eng 138:021010
Lee, Benjamin W; Liu, Bohao; Pluchinsky, Adam et al. (2016) Modular Assembly Approach to Engineer Geometrically Precise Cardiovascular Tissue. Adv Healthc Mater 5:900-6
Villasante, Aranzazu; Marturano-Kruik, Alessandro; Ambati, Srikanth R et al. (2016) Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model. Theranostics 6:1119-30
Parsa, Hesam; Ronaldson, Kacey; Vunjak-Novakovic, Gordana (2016) Bioengineering methods for myocardial regeneration. Adv Drug Deliv Rev 96:195-202
Eng, George; Lee, Benjamin W; Protas, Lev et al. (2016) Autonomous beating rate adaptation in human stem cell-derived cardiomyocytes. Nat Commun 7:10312
Spiller, Kara L; Freytes, Donald O; Vunjak-Novakovic, Gordana (2015) Macrophages modulate engineered human tissues for enhanced vascularization and healing. Ann Biomed Eng 43:616-27
Hinson, John T; Chopra, Anant; Nafissi, Navid et al. (2015) HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science 349:982-6
Sirabella, Dario; Cimetta, Elisa; Vunjak-Novakovic, Gordana (2015) ""The state of the heart"": Recent advances in engineering human cardiac tissue from pluripotent stem cells. Exp Biol Med (Maywood) 240:1008-18
Hirschi, Karen K; Li, Song; Roy, Krishnendu (2014) Induced pluripotent stem cells for regenerative medicine. Annu Rev Biomed Eng 16:277-94
Cimetta, Elisa; Vunjak-Novakovic, Gordana (2014) Microscale technologies for regulating human stem cell differentiation. Exp Biol Med (Maywood) 239:1255-63

Showing the most recent 10 out of 27 publications